Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.70 |
| ▸ | IL17A | Q16552 | 1/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.67 |
| ▸ | PARP1 | P09874 | 2/20 | 0.62 |
| ▸ | BRD1 | O95696 | 1/20 | 0.47 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430442 | 1.00 | BRD4 (0.70) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL29016699 | 0.90 | BRD4 (0.65) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL30433801 | 0.89 | BRD4 (0.71) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL120797 | 0.89 | BRD4 (0.71) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL30434430 | 0.87 | BRD4 (0.64) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL30053024 | 0.87 | BRD4 (0.69) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL150627 | 0.87 | BRD4 (0.69) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL122825 | 0.87 | BRD4 (0.64) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL122200 | 0.87 | BRD4 (0.68) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL30434122 | 0.87 | BRD4 (0.68) | BRD4IL17AHDAC1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | claimed |
| US-11938138-B2 | Methods for improved treatment of cancer | WASHINGTON UNIVERSITY (US) | 2024-03-26 | — | — | US | claimed |
| CN-111801327-B | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-02-09 | — | — | CN | claimed |
| EP-4317972-A2 | REPEAT RNA AS BIOMARKERS OF TUMOR IMMUNE RESPONSE | The General Hospital Corporation (US) | 2024-02-07 | — | — | EP | claimed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | claimed |
| US-20230310452-A1 | BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS | MDI BIOLOGICAL LABORATORY (US) | 2023-10-05 | — | — | US | claimed |
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | MEDIC LIFE SCIENCES, INC. | 2023-07-06 | — | — | US | claimed |
| EP-4157465-A2 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | Syros Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| US-20230018989-A1 | INHIBITING THE RNA METHYLTRANSFERASE METTL3 OR ITS INTERACTION WITH EIF3H TO SUPPRESS ONCOGENE TRANSLATION AND TUMORIGENESIS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-01-19 | — | — | US | claimed |
| EP-3515414-B1 | COMBINATION THERAPY | MEI PHARMA INC (US) | 2022-11-30 | — | — | EP | claimed |
| US-10111885-B2 | Compositions and therapeutic methods for the treatment of complement-associated diseases | RESVERLOGIX CORP. (CA) | 2018-10-30 | — | — | US | claimed |
| EP-3268007-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | Resverlogix Corp. (CA) | 2018-01-17 | — | — | EP | claimed |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2017-11-23 | — | — | US | claimed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | claimed |
| WO-2016147053-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | RESVERLOGIX CORP. (CA) | 2016-09-22 | — | — | WO | claimed |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2016-09-15 | — | — | US | claimed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | claimed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | claimed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BRD4 24/4885IL17A 2062/4885HDAC1 3/4885 |
| US-10111885-B2 | Compositions and therapeutic methods for the treatment of complement-associated diseases | C5, CFH, C1QBP | BRD4 3811/4885IL17A 151/4885HDAC1 2013/4885 |
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | CDKL5, KRAS, CDK9 | BRD4 183/4885IL17A 1430/4885HDAC1 3027/4885 |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 192/4885IL17A 26/4885HDAC1 639/4885 |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | C5, CFH, C1QBP | BRD4 3811/4885IL17A 151/4885HDAC1 2013/4885 |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | BRD4 10/4885IL17A 4442/4885HDAC1 30/4885 |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 192/4885IL17A 26/4885HDAC1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.